Breath takeout gives Zambon lung transplant candidate, U.S. foothold

Italian pharma Zambon is acquiring Sofinnova Partners portfolio company Breath Therapeutics for €140 million ($156 million) up front to expand its respiratory pipeline and establish a foothold in the U.S.

Shareholders of Breath Therapeutics B.V.

Read the full 340 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE